Article
A 200K SNP chip reveals a novel Pacific salmon louse genotype linked to differential efficacy of emamectin benzoate.
Marine genomics - 1 Jul 2018
Messmer Amber M, Leong Jong S, Rondeau Eric B, Mueller Anita, Despins Cody A, Minkley David R, Kent Matthew P, Lien Sigbjørn, Boyce Brad, Morrison Diane, Fast Mark D, Norman Joseph D, Danzmann Roy G, Koop Ben F
Abstract excerpt
Antiparasitic drugs such as emamectin benzoate (EMB) are relied upon to reduce the parasite load, particularly of the sea louse Lepeophtheirus salmonis, on farmed salmon. The decline in EMB treatment efficacy for this purpose is an important issue for salmon producers around the world, and particularly for those in the Atlantic Ocean where widespread EMB tolerance in sea lice is recognized as a significant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
